1. Home
  2. EXAS vs LII Comparison

EXAS vs LII Comparison

Compare EXAS & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$102.34

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Logo Lennox International Inc.

LII

Lennox International Inc.

HOLD

Current Price

$511.12

Market Cap

17.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXAS
LII
Founded
1995
1895
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
19.3B
17.7B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
EXAS
LII
Price
$102.34
$511.12
Analyst Decision
Buy
Hold
Analyst Count
19
13
Target Price
$81.27
$600.17
AVG Volume (30 Days)
2.3M
325.1K
Earning Date
02-18-2026
01-28-2026
Dividend Yield
N/A
0.99%
EPS Growth
N/A
12.46
EPS
N/A
23.67
Revenue
$3,082,033,000.00
$5,345,300,000.00
Revenue This Year
$19.40
N/A
Revenue Next Year
$13.51
$6.38
P/E Ratio
N/A
$22.22
Revenue Growth
14.47
3.77
52 Week Low
$38.81
$443.19
52 Week High
$102.66
$689.44

Technical Indicators

Market Signals
Indicator
EXAS
LII
Relative Strength Index (RSI) 83.39 49.97
Support Level $101.51 $518.66
Resistance Level $102.56 $531.86
Average True Range (ATR) 0.32 14.14
MACD -0.61 0.63
Stochastic Oscillator 81.91 44.95

Price Performance

Historical Comparison
EXAS
LII

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About LII Lennox International Inc.

Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.

Share on Social Networks: